18F-FDOPA PET/CT Findings in a Patient With Primary Cerebral Amyloidoma. (April 2020)

• Record Type: Journal Article
• Authors: Rozenblum, Laura; Bertaux, Marc; Bielle, Franck; Ollivier, Morgan; Choquet, Sylvain; Garcilazo, Ytel; Mokhtari, Karima; Kas, Aurélie
• Is Part Of: Clinical nuclear medicine. Volume 45:Number 4(2020)
• Publication Date: 2020-04
• Subjects: brain amyloidoma -- 18F-FDOPA PET -- LAT1; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002959
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Amino acid PET, including 18 F-FDOPA, is recommended for initial characterization, delineation of tumor extent, and follow-up of gliomas because of its high diagnostic performances. 18 F-FDOPA accumulates inside tumor cells via the L-type amino acid transporter 1 (LAT1) whose expression is increased in gliomas. We report here a case of a histopathologically proven brain amyloidoma that was first addressed for a suspected glioma. Congo red staining showed scattered extracellular deposits of amyloid and immunohistochemistry-highlighted LAT1 expression, explaining the high 18 F-FDOPA uptake found in this lesion. This case indicates that differential diagnosis of the 18 F-FDOPA uptake in brain lesions should include amyloidoma.